Legal & General Group
TPTX

Legal & General Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Legal & General Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,898
Closed -$3.08M – 3528
2022
Q2 		$3.08M Buy
40,898
+3,919
+11% +$174K ﹤0.01% 1665
2022
Q1 		$993K Buy
36,979
+646
+2% +$21.7K ﹤0.01% 2235
2021
Q4 		$1.73M Hold
36,333
– – ﹤0.01% 2082
2021
Q3 		$2.41M Buy
36,333
+8,205
+29% +$585K ﹤0.01% 1932
2021
Q2 		$2.19M Buy
28,128
+3,983
+16% +$294K ﹤0.01% 1927
2021
Q1 		$2.28M Buy
24,145
+2,484
+11% +$295K ﹤0.01% 1926
2020
Q4 		$2.64M Buy
21,661
+1,342
+7% +$147K ﹤0.01% 1775
2020
Q3 		$1.77M Buy
20,319
+4,279
+27% +$298K ﹤0.01% 1812
2020
Q2 		$1.04M Buy
16,040
+896
+6% +$51.7K ﹤0.01% 1973
2020
Q1 		$676K Buy
15,144
+8,805
+139% +$468K ﹤0.01% 1979
2019
Q4 		$394K Buy
6,339
+5,233
+473% +$249K ﹤0.01% 2267
2019
Q3 		$42K Hold
1,106
– – ﹤0.01% 2812
2019
Q2 		$45K Buy
+1,106
New +$39.5K ﹤0.01% 2822

Legal & General Group's TPTX Position: Q3 2022 in Review

Legal & General Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 40,898 shares — an estimated $3.08M sold.

Legal & General Group first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $3.08M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Legal & General Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 40,898 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3.08M.
  • Legal & General Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Legal & General Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.08M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.